This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its newer blockbuster drugs like Prolia/Xgeva
3 Top Dividend Stocks to Maximize Your Retirement Income - March 30, 2020
by Zacks Equity Research
The traditional approaches to retirement planning are longer covering all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
Pharma, Biotech Players Step Up Efforts Against Coronavirus
by Indrajit Bandyopadhyay
Several pharma & biotech companies announce their plan to fight coronavirus pandemic and state anticipated unfavorable impact of the outbreak on their business.
CytomX & Astellas Collaborate to Develop Novel Cancer Therapy
by Zacks Equity Research
CytomX (CTMX) and Astellas Pharma sign collaboration agreement to develop novel cancer therapy using CytomX's Probody therapeutic technology platform.
How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks - March 23, 2020
by Zacks Equity Research
The traditional approaches to retirement planning are longer covering all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
3 Top Dividend Stocks to Maximize Your Retirement Income - March 16, 2020
by Zacks Equity Research
The traditional approaches to retirement planning are longer covering all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
Is Amgen (AMGN) Truly One of the Best Biotech Stocks to Own?
by Zacks Equity Research
Amgen (AMGN) boasts a strong biosimilars portfolio, which can drive long-term growth. Amgen is also progressing with its pipeline while regularly pursuing business development deals.
Top Analyst Reports for Alphabet, Procter & Gamble & Royal Dutch Shell
by Mark Vickery
Today's Research Daily features new research reports on 12 major stocks, including Alphabet (GOOGL), Procter & Gamble (PG) and Royal Dutch Shell (RDS.A).
3 Top Dividend Stocks to Maximize Your Retirement Income - March 03, 2020
by Zacks Equity Research
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
Merck's Keytruda Improves PFS in Phase III Lymphoma Study
by Zacks Equity Research
Merck's (MRK) Keytruda significantly improves progression-free survival compared with brentuximab vedotin in patients with relapsed or refractory classical Hodgkin Lymphoma (cHL)
Radius (RDUS) Q4 Earnings Beat Estimates on Tymlos Strength
by Zacks Equity Research
Radius (RDUS) reports narrower-than-expected loss and beats sales estimates in the fourth quarter of 2019 as Tymlos gains traction.
Why Is Amgen (AMGN) Down 11.7% Since Last Earnings Report?
by Zacks Equity Research
Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Esperion (ESPR) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Esperion Therapeutics (ESPR) reports encouraging fourth-quarter results. The company is set to launch its first drug next month.
3 Top Dividend Stocks to Maximize Your Retirement Income - February 26, 2020
by Zacks Equity Research
The traditional approaches to retirement planning are longer covering all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
Guardant Health (GH) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
During Guardant Health's (GH) Q4 earnings call, investors' focus will be on the updates related to Guardant360 test and the colorectal cancer screening rates of its LUNAR-2 blood test.
What's in the Cards for Amarin (AMRN) This Earnings Season?
by Zacks Equity Research
Amarin's (AMRN) fourth-quarter results are likely to reflect strong demand for its cardiovascular drug, Vascepa.
Bull of the Day: Guardant Health (GH)
by Kevin Cook
Cancer diagnostics provider who delivered 181% revenue growth and 18,500 tests to patients and labs partners with Amgen
Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FTCS
Can Biotech ETFs Gain on Mixed Q4 Earnings Results?
by Sweta Jaiswal, FRM
Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry, post their Q4 earnings releases.
Western Union (WU) Q4 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Western Union (WU) delivered earnings and revenue surprises of -11.63% and -1.00%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
VAREX IMAGING (VREX) Q1 Earnings Miss Estimates
by Zacks Equity Research
VAREX IMAGING (VREX) delivered earnings and revenue surprises of -25.00% and 4.87%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Diodes (DIOD) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Diodes (DIOD) delivered earnings and revenue surprises of 3.17% and 0.39%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
J&J Files Application for Darzalex Label Expansion With FDA
by Zacks Equity Research
J&J (JNJ) seeks approval for new Darzalex combo regimen in the United States to treat relapsed/refractory multiple myeloma patients who have received one to three prior lines of therapy.
Roche Reports Disappointing Data on Alzheimer's Disease Drug
by Zacks Equity Research
Roche's (RHHBY) Alzheimer's disease drug fails to meet primary endpoint in a phase II/III study.
The Zacks Analyst Blog Highlights: Alphabet, Roche, Amgen, General Electric and Sony
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alphabet, Roche, Amgen, General Electric and Sony
Ligand (LGND) Q4 Earnings & Revenues Top Estimates, Stock Up
by Zacks Equity Research
Ligand (LGND) reports higher-than-expected fourth-quarter 2019 earnings and revenues.